Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Corcept Therapeutics (CORT) over the last 10 years, with Q3 2025 value amounting to $69.6 million.

  • Corcept Therapeutics' Receivables - Net rose 1659.83% to $69.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.6 million, marking a year-over-year increase of 1659.83%. This contributed to the annual value of $54.0 million for FY2024, which is 3125.5% up from last year.
  • Latest data reveals that Corcept Therapeutics reported Receivables - Net of $69.6 million as of Q3 2025, which was up 1659.83% from $64.6 million recorded in Q2 2025.
  • Corcept Therapeutics' 5-year Receivables - Net high stood at $69.6 million for Q3 2025, and its period low was $22.2 million during Q1 2021.
  • In the last 5 years, Corcept Therapeutics' Receivables - Net had a median value of $32.6 million in 2023 and averaged $41.4 million.
  • As far as peak fluctuations go, Corcept Therapeutics' Receivables - Net tumbled by 1680.41% in 2021, and later skyrocketed by 8895.48% in 2024.
  • Corcept Therapeutics' Receivables - Net (Quarter) stood at $27.6 million in 2021, then grew by 12.42% to $31.1 million in 2022, then surged by 32.41% to $41.1 million in 2023, then surged by 31.26% to $54.0 million in 2024, then increased by 29.0% to $69.6 million in 2025.
  • Its Receivables - Net was $69.6 million in Q3 2025, compared to $64.6 million in Q2 2025 and $61.8 million in Q1 2025.